NASDAQ:COGT

Cogent Biosciences - COGT Stock Forecast, Price & News

$12.15

-0.35 (-2.80%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $11.85
▼
$12.60
50-Day Range: $10.87
▼
$15.16
52-Week Range: $3.79
▼
$18.07

Volume: 910,741 shs
Average Volume: 1.24 million shs
Market Capitalization: $556.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.33

Cogent Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 50.9% Upside
$18.33 Price Target
Short Interest: Bearish
10.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.31) to ($2.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

847th out of 1,023 stocks

Pharmaceutical Preparations Industry

415th out of 501 stocks

3.5

Analyst's Opinion

Consensus Rating
Cogent Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.33, Cogent Biosciences has a forecasted upside of 50.9% from its current price of $12.15.
Amount of Analyst Coverage
Cogent Biosciences has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.41% of the outstanding shares of Cogent Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Cogent Biosciences has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Cogent Biosciences has recently increased by 1.92%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cogent Biosciences does not currently pay a dividend.
Dividend Growth
Cogent Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COGT.

2.6

News and Social Media Coverage

News Sentiment
Cogent Biosciences has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cogent Biosciences this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cogent Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Cogent Biosciences is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.31) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cogent Biosciences is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cogent Biosciences is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cogent Biosciences has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cogent Biosciences (NASDAQ:COGT) Stock

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Stock News Headlines

December 5, 2022 | finance.yahoo.com

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

November 28, 2022 | finance.yahoo.com

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

November 14, 2022 | finanznachrichten.de

Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

November 14, 2022 | finance.yahoo.com

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

November 9, 2022 | finance.yahoo.com

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

November 3, 2022 | finance.yahoo.com

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

October 26, 2022 | finance.yahoo.com

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

September 22, 2022 | finance.yahoo.com

Cogent Biosciences, Inc. (COGT)

September 20, 2022 | seekingalpha.com

COGT Cogent Biosciences, Inc.

September 13, 2022 | seekingalpha.com

Cogent Biosciences: What's Ahead

August 4, 2022 | finance.yahoo.com

Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth

July 12, 2022 | finance.yahoo.com

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?

July 12, 2022 | finance.yahoo.com

Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength

June 20, 2022 | finance.yahoo.com

Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions?

June 16, 2022 | finance.yahoo.com

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 13, 2022 | seekingalpha.com

Reviewing Cogent Biosciences After Last Week's Data

June 13, 2022 | finance.yahoo.com

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

June 13, 2022 | seekingalpha.com

Cogent Biosciences trades in red on $125M stock offering

June 10, 2022 | markets.businessinsider.com

Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump

June 10, 2022 | nasdaq.com

Cogent Biosciences Reports Positive Initial Clinical Data From APEX Study Of Bezuclastinib

June 10, 2022 | finance.yahoo.com

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

June 6, 2022 | finance.yahoo.com

Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET

May 10, 2022 | seekingalpha.com

Cogent Biosciences reports Q1 results

May 10, 2022 | finance.yahoo.com

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

May 6, 2022 | seekingalpha.com

Cogent Biosciences files for $300M mixed shelf offering

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Company Calendar

Last Earnings: 11/10/2021
Today: 12/06/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:COGT
CUSIP: N/A
CIK: 1460329
Web: www.cogint.com
Phone: (617) 945-5576
Fax: N/A
Employees: 77
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.33
High Stock Price Forecast: $19.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +50.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -70.69%
Return on Assets: -44.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.59
Quick Ratio: 12.59

Sales & Book Value

Annual Sales: $7.87 million
Price / Sales: 70.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.23 per share
Price / Book: 3.76

Miscellaneous

Outstanding Shares: 45,819,000
Free Float: 43,986,000
Market Cap: $556.70 million
Optionable: Not Optionable
Beta: 1.67

Key Executives

Mr. Andrew R. Robbins M.B.A. (Age 46)
Pres, CEO & Director
Comp: $961.32k

Dr. John Edward Robinson Ph.D.
Chief Scientific Officer

Dr. Jessica Sachs M.D. (Age 47)
Chief Medical Officer
Comp: $595.24k

Mr. John L. Green C.A. (Age 42)
CPA, CFO & Principal Accounting Officer

Mr. Brad Barnett
Chief Technology Officer

Mr. Evan D. Kearns J.D. (Age 42)
Chief Legal Officer & Corp. Sec.

Ms. Erin Schellhammer
Chief People Officer

Ms. Sara Saltzman
Sr. VP of Regulatory Affairs

Mr. Dana R. Martin Pharm.D.
Sr. VP of Medical Affairs & Chief Patient Officer

Brad Fell
VP & Head of Medicinal Chemistry

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

COGT Stock - Frequently Asked Questions

Should I buy or sell Cogent Biosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COGT shares.
View COGT analyst ratings or view top-rated stocks.
What is Cogent Biosciences' stock price forecast for 2023?: 2 Wall Street analysts have issued 1 year target prices for Cogent Biosciences' stock. Their COGT share price forecasts range from $18.00 to $19.00. On average, they expect the company's share price to reach $18.33 in the next year. This suggests a possible upside of 50.9% from the stock's current price.
View analysts price targets for COGT or view top-rated stocks among Wall Street analysts.
How have COGT shares performed in 2022?: Cogent Biosciences' stock was trading at $8.58 on January 1st, 2022. Since then, COGT stock has increased by 41.6% and is now trading at $12.15.
View the best growth stocks for 2022 here.
When is Cogent Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our COGT earnings forecast.
How were Cogent Biosciences' earnings last quarter?: Cogent Biosciences, Inc. (NASDAQ:COGT) announced its earnings results on Wednesday, November, 10th. The technology company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.07.

What other stocks do shareholders of Cogent Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).
What is Cogent Biosciences' stock symbol?: Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."
Who are Cogent Biosciences' major shareholders?: Cogent Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.03%), Commodore Capital LP (9.43%), RA Capital Management L.P. (8.76%), State Street Corp (7.44%), Perceptive Advisors LLC (7.00%) and Vanguard Group Inc. (6.95%). Insiders that own company stock include Fairmount Funds Management Llc and John L Green.
View institutional ownership trends.
How do I buy shares of Cogent Biosciences?: Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cogent Biosciences' stock price today?: One share of COGT stock can currently be purchased for approximately $12.15.
How much money does Cogent Biosciences make?: Cogent Biosciences (NASDAQ:COGT) has a market capitalization of $556.70 million and generates $7.87 million in revenue each year. The technology company earns $-72,270,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.
How can I contact Cogent Biosciences?: Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The official website for the company is www.cogint.com. The technology company can be reached via phone at (617) 945-5576 or via email at jkopin@cogint.com.

This page (NASDAQ:COGT) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial